Acceleron Pharma (XLRN) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Acceleron Reports Third Quarter 2019 Operating and Financial Results
November 6, 2019 7:53 AM EST- FDAs review of luspatercept BLA for the beta-thalassemia and lower-risk MDS indications remains ongoing -
- Six clinical abstracts accepted for presentation at the 61st American Society of Hematology (ASH) Annual Meeting -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2019.
With the FDAs decision on... More
